The Evolving Economy

What impact could robotic surgery have on the future of healthcare?

  • Technological advancements have seen the application of surgical robots broaden over time to include general surgery and delicate operations
  • Only 4% of surgery globally is done with robots, with most of these procedures performed in the US
  • We believe the applications in robotic surgery will continue to widen by both procedure type and region, creating compelling investment opportunities

Surgical robots have been around since the 1980s, with the Puma 560 used in 1985 by Kwoh et al to perform neurosurgical biopsies and non-laparoscopic surgery with greater precision.[1]

As technology and surgical developments have rapidly advanced over the years, so too has the general perception of robots – moving from science fiction to cutting-edge technology that could ultimately revolutionise healthcare.

More than 30 years later, the influence of surgical robots in operating rooms is growing at pace. Only 4% of surgery globally is done with robots[2], with most of these procedures performed in the US. While this figure may currently sound small, we believe this highlights the huge growth potential for geographic expansion in the coming years.

The benefits of robotic surgery include:

  • Enhanced dexterity: Surgeons are able to operate in very tight spaces in a body that would otherwise only be accessible through open surgery;
  • Greater precision and control: Surgical robots help surgeons with the positioning and manipulation of surgical instruments;
  • Shorter hospital stays: The smaller incisions will likely mean faster recovery times for patients and, generally, lower readmission rates.

Read more: How will digitalization create a more resilient post-pandemic world?

Examples of procedures fueling innovation in robotic surgery

Over time, the application of surgical robots has significantly widened - from general laparoscopic procedures such as hernia and colorectal surgery to delicate operations on the heart and spine, knee replacements and removing brain tumours. Below are some examples of companies leading innovation in robotic surgery:

  • General surgery

At the forefront of the developments in these types of procedures is Intuitive Surgical*, which manufactures robotic-assisted medical equipment to support doctors and hospitals in minimally invasive surgery. It pioneered the groundbreaking da Vinci system, with almost 6,000 in existence around the world and a surgeon starting a da Vinci procedure every 25.4 seconds. In 2020, da Vinci Surgical Systems were used to perform 1.2mn procedures, a marginal increase from 2019 – and a significant figure, given that some surgeries had been postponed due to the COVID-19 pandemic.

Launched in 1998, Intuitive Surgical’s da Vinci system was one of the first robotic-assisted systems approved by the US Food and Drug Administration (FDA) for general laparoscopic surgery. Intuitive’s status as a key player is backed up by a comprehensive training programme for academics and future doctors, and reinvestments in research and development – its annual spend on the latter has almost tripled from $197mn in 2015 to over $500mn in 2019 and 2020.

  • Spine surgery

Globus Medical* is a leading medical device manufacturer, focusing on musculoskeletal implants that provide spine care solutions for patients. One of its solutions is the ExcelsiusGPS, a robotic arm with complete navigation capabilities in one adaptable platform for accurate alignment in spine surgery. It means surgeons can visualise, plan and navigate patient anatomy – as well as receive navigation feedback throughout the procedure - in real-time. The company has also developed orthopaedic trauma solutions in recent years to diversify beyond the spine market.

  • Knee replacements

The global share of older people (60+) is expected to increase by 42% from 2018 to 2030 – five times faster than the under 60 population.[3] As you age, knee joints run the risk of becoming worn or damaged over time, with knee replacement surgery generally carried out on the 60-80 age bracket.[4] Many people also live more active lifestyles into older age, compared to previous generations. This means more people may find they need knee surgery in their later years.

Zimmer Biomet* is a US healthcare company that specialises in knee surgery. Its ROSA Knee robotic technology is designed to help a specially trained surgeon tailor the placement of knee implants. Zimmer has also developed its mymobility app, in collaboration with Apple, to inform care decisions and further enhance the communication between patients and their surgeons.

Read more: How has the pandemic impacted the outlook for robotics?

Huge growth potential around the world

The global market for robotic surgery equipment is expected to achieve a compound annual growth rate of 30% until 2023.[5] The COVID-19 pandemic meant that hospitals around the world were forced to delay many non-urgent surgeries in which robots could have supported. However, going forward, the containment of the disease through the rollout of vaccines will likely normalise hospitals’ operational capacity, leading to a surge in postponed robotic surgeries being performed.

Another reason for optimism is likely to come in the form of new market entrants, with the low market penetration allowing different companies to develop solutions that address a range of issues. For example, Johnson & Johnson* has a growing market presence, particularly with its acquisition of Auris Health – a robotic technology platform focused on lung diagnostics and procedures. Elsewhere, Medtronic*, a global medical device manufacturer, is in the process of developing a surgical robot.

With new entrants comes the potential for more innovation, thanks to disruptive technology like image-guided robotic interventions and enhanced motion control for greater precision. Coupled with 5G and AI[6], developments in these areas will likely increase the types of robotic-assisted surgical procedures performed in the future – for example, the removal of tumours from parts of the body that would otherwise be difficult to reach. As a result, we expect this will create compelling investment opportunities within robotic surgery over the coming years.

Read more: Post-COVID-19, innovation in healthcare is here to stay

 

Sources:

* All stocks mentioned are for illustrative purposes only and should not be considered as advice or a recommendation for an investment strategy. All company information can be found on their websites and is accurate as at 28 February 2021.
[1] YS Kwoh, J Hou, EA Jonckheere at al. A robot with improved absolute positioning accuracy for CT guided stereotactic brain surgery. IEEE Trans Biomed Eng 1988
[2] Bank of America Merrill Lynch, global research estimates, December 2020
[3] Bank of America Merrill Lynch Silver Dollar / Longevity Report, May 2016
[4] NHS UK, August 2019
[5] International Federation of Robotics 2020
[6] AI refers to artificial intelligence

This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. 

It has been established on the basis of data, projections, forecasts, anticipations and hypothesis which are subjective. Its analysis and conclusions are the expression of an opinion, based on available data at a specific date. 
All information in this document is established on data made public by official providers of economic and market statistics. AXA Investment Managers disclaims any and all liability relating to a decision based on or for reliance on this document. All exhibits included in this document, unless stated otherwise, are as of the publication date of this document. 
Furthermore, due to the subjective nature of these opinions and analysis, these data, projections, forecasts, anticipations, hypothesis, etc. are not necessary used or followed by AXA IM’s portfolio management teams or its affiliates, who may act based on their own opinions. Any reproduction of this information, in whole or in part is, unless otherwise authorised by AXA IM, prohibited.